Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

's clinical development plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering- Plough's Securities and Exchange Commission filings, including Part I, Item 1A. "Risk Factors" in Schering-Plough's 2007 10-K/A.

References

1 Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med

Res (2007) 12: 385-390.

2 Atazanavir sulfate is a Bristol-Myers Squibb Company prescription

medicine. Please see the atazanavir product insert for information on

this product.

3 Truvada is a registered trademark of Gilead Sciences, Inc. Please see

the Truvada product insert for information on this product.

4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent,

sustained suppression of viral replication in treatment-experienced

adults: VICTOR-E1 48-week results (39LB); 15th Conference on

Retroviruses and Opportunistic Infections (CROI); February 2008; Boston.

5 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV)

in HIV-infected treatment-experienced subjects: 48 week results

(TUAB102); International AIDS Society 4th IAS Conference on HIV

Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.

6 Hammer SM, Schechter M, Montaner JS, et al. Treatment for
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... will present new data across its portfolio representing ... rare and difficult-to-treat cancers.  These results will be ... for Medical Oncology (ESMO) Congress in Milan, Italy ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) "Pfizer ...
... Oct. 7 Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) ... treatment-naive patients with primary immunodeficiency (PI) and may ... therapy in the newly diagnosed, according to data ... European Society for Immunodeficiencies. The study found that ...
Cached Medicine Technology:Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 3Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 4Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 5Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 6Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 7Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 8Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 9Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 10Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 11Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 12Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 2Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 3Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 4
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... issue of American Journal of Preventive Medicine says that there ... ,These conclusions were arrived at by researchers at ... Centers for Disease Control and Prevention. They monitored data of ... Factor Surveillance System survey. This particular survey covered 22 states ...
... appearing in the online journal Cancer says that elderly white ... to develop full blown melanoma regardless of their exposure to ... study found that women in the age group of 50 ... carcinoma or squamous cell carcinoma of the skin, had a ...
... attempt to rapidly eliminate milder strains of avian influenza virus ... been proposed to broaden the target of the European Union ... been taken by agricultural ministers of the 25 different countries ... the proposal, it was agreed to boost the currently existing ...
... into the oral HIV tests which have given false results. ... California and New York health centers. The rapid OraQuick Advance ... minutes. The test had gained popularity as blood samples are ... ,Complaints are being investigated by officials belonging to ...
... Hickok, neuroscientist, professor of cognitive sciences at the University ... The National Institute of //Deafness and Other Communication Disorders ... Health ($2.4 million for 5 years). ,This ... brain converts sound waves into meaningful language. ...
... health hospitals are flooded with patients with psychiatric disorders. The ... 12% in the past 4 years. ,This ... health facilities. ,According to the Australian Institute of ... specialized psychiatric hospitals decreased by 5%. ,But the ...
Cached Medicine News:Health News:Detection of Weak strains of bird flu virus – Target of European Unio 2Health News:$2.4 Million Grant To Unravel The Mystery Of Language Recognition. 2Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
... Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing powder EEO(-m r ... Point (3%): less than or equal to 35.5C ... 80C Gel Strength (1.5%): greater than or equal ... greater than or equal to 1500 gm/cm 2 ...
... sulfate (SO 4 ) ≤ 6000 mg/kg Cation traces: ... ≤ 10 mg/kg Cr ≤ 10 mg/kg Cu ≤ ... mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 mg/kg ... ≤ 10 mg/kg Zn ≤ 10 mg/kg Special ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Medicine Products: